Sign In
Buy RVMD
$169.51
+3.70 (+2.23%)
At Close: Jun 23, 2026
Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.
08:00am, Monday, 22'nd Jun 2026
Steve Kelsey, president, R&D, to transition to senior advisor to CEO ahead of planned retirement in January 2027 Company announces new R&D leadership structure to support continued execution of strate
Revolution Medicines: Strong Data, Big Market (Rating Upgrade)
05:04am, Saturday, 13'th Jun 2026
Revolution Medicines is upgraded to buy as Daraxonrasib delivers practice-changing Phase 3 data in pancreatic ductal adenocarcinoma (PDAC). RVMD's $4B pro forma liquidity supports over two years of ag
Can Revolution Medicines Be a Game-Changer Stock?
06:45am, Thursday, 11'th Jun 2026
Revolution Medicines' promising pancreatic cancer therapy could be approved later this year. The clinical-stage company has more than $4 billion in cash to develop and market its drugs.
Why Is Revolution Medicines (RVMD) Up 9.3% Since Last Earnings Report?
12:35pm, Friday, 05'th Jun 2026
Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock?
Healthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotech
08:45am, Friday, 05'th Jun 2026
Compare risk profiles, dividend strategies, and portfolio concentration as these two healthcare ETFs take different paths to long-term returns.
Revolution Medicines Is Up 97% This Year: Here Are the Bull and Bear Cases for This Soaring Biotech Stock.
02:45am, Friday, 05'th Jun 2026
Can the drugmaker justify its valuation?
Revolution Medicines, Inc. (RVMD) Discusses Positive Clinical Results and Implications for Metastatic Pancreatic Cancer Treatment Transcript
RVMD Stock Rises on Detailed Results From Pancreatic Cancer Study
10:16am, Monday, 01'st Jun 2026
Revolution Medicines jumps after detailed phase III data show daraxonrasib cuts death risk by 60% and doubles median survival in treated pancreatic cancer.
Revolution Medicines Jumps 12% As Cancer Drug Data Strengthens Case
09:26am, Monday, 01'st Jun 2026
Revolution Medicines (RVMD) moved higher in US premarket trading after fresh data added more weight to the story around daraxonrasib, its experimental pancreati
Revolution Medicines' Pancreatic Cancer Pill Doubles Survival, Cuts Death Risk 60% in Trial As Stock Sits Near All-Time Highs
10:43pm, Sunday, 31'st May 2026
Few cancers have proven as difficult to treat as pancreatic cancer, making any sign of a survival breakthrough a major event for both patients and investors.
Results simultaneously published in The New England Journal of Medicine Results simultaneously published in The New England Journal of Medicine
VHT vs. XBI: Vanguard Health Care ETF Tops SPDR Biotech in Yield and Cost
08:07am, Thursday, 28'th May 2026
Expense ratios, yield, and sector breadth set these healthcare ETFs apart-see how their risk profiles and portfolio strategies compare.
Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation
04:05pm, Thursday, 21'st May 2026
REDWOOD CITY, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted ca
GraniteShares Files High-Octane 2X ETFs Tied To Nuclear, AI, Biotech Momentum Stocks
09:50am, Tuesday, 19'th May 2026
GraniteShares has filed with the U.S. Securities and Exchange Commission to launch three new leveraged single-stock ETFs tied to high-volatility themes spanning nuclear energy, AI infrastructure and b
Cancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: Report
11:47am, Friday, 15'th May 2026
U.S. cancer centers are moving quickly to enroll patients in an expanded access program for a pancreatic cancer drug developed by Revolution Medicines Inc. (NASDAQ:RVMD) after clinical trial results s
